Physician profile
James Ohara
NPI 1770584724
$3,456.00
in general payments reported to CMS, 2019-2025
33 companies · $47.87 in 2025
The $47.87 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $304 · 2021: $302 · 2022: $917 · 2023: $949 · 2024: $74.12 · 2025: $47.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.98 | 2019-2023 | Jardiance, Tradjenta |
| Pfizer INC. | $339.97 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $267.54 | 2022-2025 | Eliquis |
| Novo Nordisk INC | $216.65 | 2021-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $188.38 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $183.55 | 2019-2023 | |
| Amarin Pharma, INC. | $172.28 | 2019-2023 | |
| Abbott Laboratories | $158.38 | 2021-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.16 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $155.31 | 2020-2023 | Lagevrio, Dificid, Pneumovax 23 |
| Lilly USA, LLC | $138.83 | 2019-2023 | Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $129.28 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $116.06 | 2019-2023 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $111.82 | 2019-2023 | |
| Astellas Pharma US INC | $82.18 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $78.67 | 2019-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $52.97 | 2019 | |
| Hikma Pharmaceuticals USA | $48.98 | 2020-2022 | |
| Allergan, INC. | $45.33 | 2019-2020 | |
| Exact Sciences Corporation | $44.18 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $41.83 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $40.53 | 2022-2023 | Quviviq |
| Shire North American Group INC | $30.15 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.83 | 2022 | |
| Genentech USA, INC. | $25.94 | 2019 | |
| Dexcom, INC. | $24.60 | 2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $22.39 | 2023 | Injectafer |
| Vbi Vaccine (Delaware) INC. | $21.13 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.56 | 2023 | Strensiq |
| Eisai INC. | $17.41 | 2021 | |
| Mylan Specialty L.P. | $16.57 | 2020 | |
| Sanofi Pasteur INC. | $16.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ohara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.